Publication: LBA10 Bemarituzumab (BEMA) plus chemotherapy for advanced or metastatic FGFR2b-overexpressing gastric or gastroesophageal junction cancer (G/GEJC): FORTITUDE-101 phase III study results
| dc.contributor.author | S.Y. Rha | |
| dc.contributor.author | R.A. Pazo Cid | |
| dc.contributor.author | A. Fernandez Montes | |
| dc.contributor.author | S. Qin | |
| dc.contributor.author | S.J. Klempner | |
| dc.contributor.author | A. Elme | |
| dc.contributor.author | H.M. Türk | |
| dc.contributor.author | C. Pozzo | |
| dc.contributor.author | A. Ranceva | |
| dc.contributor.author | J. Li | |
| dc.contributor.author | H. Yoon | |
| dc.contributor.author | Z.A.A. Wainberg | |
| dc.contributor.author | A. Zahlten-Kuemeli | |
| dc.contributor.author | P. Yen | |
| dc.contributor.author | S. Kaur | |
| dc.contributor.author | K. Muro | |
| dc.contributor.author | E.C. Smyth | |
| dc.contributor.institutionauthor | TÜRK, HACI MEHMET | |
| dc.date.accessioned | 2026-10-25T13:40:12Z | |
| dc.date.issued | 2025-09-01 | |
| dc.identifier.doi | 10.1016/j.annonc.2025.09.092 | |
| dc.identifier.issn | 0923-7534 | |
| dc.identifier.startpage | S1620 | |
| dc.identifier.uri | https://doi.org/10.1016/j.annonc.2025.09.092 | |
| dc.identifier.uri | https://hdl.handle.net/20.500.12645/42753 | |
| dc.identifier.volume | 36 | |
| dc.language.iso | en | |
| dc.publisher | Elsevier BV | |
| dc.relation.ispartof | Annals of Oncology | |
| dc.rights | openAccess | |
| dc.source | OpenAire | |
| dc.title | LBA10 Bemarituzumab (BEMA) plus chemotherapy for advanced or metastatic FGFR2b-overexpressing gastric or gastroesophageal junction cancer (G/GEJC): FORTITUDE-101 phase III study results | en |
| dc.type | Article | |
| dspace.entity.type | Publication | |
| relation.isAuthorOfPublication | 1b3a1540-7e57-405d-8a9d-f926d17dcc29 | |
| relation.isAuthorOfPublication.latestForDiscovery | 1b3a1540-7e57-405d-8a9d-f926d17dcc29 |